HRS-4508 clinical trials
Also written HRS-4508.
How each study uses HRS-4508 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-4508 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Jiangsu HengRui Medicine Co., Ltd. (5) · Fudan University (1)
Often tested with
Tested in the same studies.
HRS-6209 (2) · Trastuzumab rezetecan (2) · HRS-9813 (1) · Dalpiciclib (1) · Pyrotinib (1) · Adebrelimab (1) · Camrelizumab (1) · Tizetatug rezetecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test HRS-4508.
- Sep 2027A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
- Oct 2027A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses HRS-4508 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06555068Written as HRS-6209 in Combination HRS-4508 and letrozole
- A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06598735Written as HRS-4508
- A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07140393Written as HRS-4508+ Capecitabine
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as HRS-4508
- A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07003321Written as HRS-4508 tablet
- A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07232849Written as HRS-4508 tablet